Novo Nordisk hopes that new data supporting the cardiovascular and glycaemic safety of its Tresiba long-acting insulin will prove a game-changer in the US.
California has said it will start selling its own generic version of overdose reversal agent naloxone in another example of the use of government-level purchasing power to
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.